Citius Pharma Q2 net loss $8.5M; LYMPHIR PDUFA Aug 13, Mino-Lok data due Q2

Citius Pharmaceuticals, Inc.

2025-Q2 EPS reported -$2.79 vs consensus -$0.60 ▼ miss (-363.6%)

Cash $12.6M at Mar 31; $15M April offering extends runway through Dec 2024.
LYMPHIR BLA accepted with PDUFA target date August 13, 2024.
Mino-Lok Phase 3 topline results anticipated in calendar Q2 2024.
Merger of oncology sub with TenX (TENK) progressing; pending SEC/TENK approval.
Net loss $8.5M ($0.05/shr) vs $10.5M loss a year ago; R&D expense down.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Citius Pharmaceuticals, Inc. reported fiscal second quarter 2024 ended March 31, 2024 results: net income Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3, EPS ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024.

Period: fiscal second quarter 2024 ended March 31, 2024
Net income: Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3
EPS: ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024
Result: reported results

Exact text from the filing

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-042966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.